CSIMarket Company Name, Ticker, Customers, else..
 
Monte Rosa Therapeutics Inc   (NASDAQ: GLUE)
Other Ticker:  
 
 
Price: $5.6550 $-0.11 -1.823%
Day's High: $5.91 Week Perf: -0.09 %
Day's Low: $ 5.55 30 Day Perf: -26.37 %
Volume (M): 631 52 Wk High: $ 12.40
Volume (M$): $ 3,569 52 Wk Avg: $5.83
Open: $5.79 52 Wk Low: $3.21



 Market Capitalization (Millions $) 464
 Shares Outstanding (Millions) 82
 Employees 85
 Revenues (TTM) (Millions $) 15
 Net Income (TTM) (Millions $) -119
 Cash Flow (TTM) (Millions $) 67
 Capital Exp. (TTM) (Millions $) 5

Monte Rosa Therapeutics Inc
Monte Rosa Therapeutics Inc is a biopharmaceutical company that focuses on developing innovative small molecule therapeutics targeting protein degradation pathways. The company aims to harness the body's natural protein degradation system to selectively eliminate disease-causing proteins, potentially leading to the development of novel treatments for various diseases including cancer and genetic disorders. Monte Rosa Therapeutics utilizes its proprietary platform technology to discover and optimize small molecules that can degrade specific proteins, offering a unique approach to drug development.


   Company Address: 321 Harrison Avenue Boston 2118 MA
   Company Phone Number: 949-2643   Stock Exchange / Ticker: NASDAQ GLUE


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMGN        0.71% 
CCCC        12.57% 
CRIS   -2.08%    
EXEL        2.55% 
KRYS   -1.28%    
TWST        9.13% 
• View Complete Report
   



Clinical Study

Innovating Oncology Monte Rosa Therapeutics Advances Molecular Glue Degraders in Breast Cancer and Beyond

Published Mon, Dec 30 2024 2:15 AM UTC

In the rapidly evolving landscape of oncology therapeutics, the innovations brought forth by Monte Rosa Therapeutics present a notable advancement in the targeted treatment of breast cancer and potentially other diseases. Recent presentations at prestigious medical conferences highlight promising preclinical data regarding the company?s CDK2-directed molecular glue degraders...
Clinical Study

Innovating Inflammation Monte Rosa Therapeutics MRT-6160 and MRT-8102 Pave the Way for Next-Generation IBD Treatment...

Published Mon, Aug 19 2024 11:00 AM UTC

Emerging Therapeutics: Advancements in the Development of MRT-6160 and MRT-8102 by Monte Rosa Therapeutics In the rapidly evolving landscape of targeted therapies for challenging health conditions, Monte Rosa Therapeutics is making significant strides with its innovative approaches to drug development. The recent announcements concerning the Phase 1 study of MRT-6160 and th...
Clinical Study

Unleashing Therapeutic Potential Monte Rosa Therapeutics Forging Ahead with MRT-2359, MRT-6160, and MRT-8102...

Published Thu, Jun 27 2024 11:00 AM UTC

Monte Rosa Therapeutics, a leading biotechnology company, has recently provided updates on the development progress of three promising therapeutic candidates: MRT-2359, MRT-6160, and MRT-8102. These advancements demonstrate the company s commitment to addressing unmet medical needs using innovative approaches such as molecular glues and pathway inhibitors. This article aims...
Clinical Study

Monte Rosa Therapeutics Unveils Promising Preclinical Data at Digestive Disease Week 2024, Propelling Excitement for a Revolutionary Treatment for Inflammatory Bowel Disease.

Published Tue, May 21 2024 11:00 AM UTC

Monte Rosa Therapeutics Presents Promising Preclinical Data at Digestive Disease Week 2024, Showcasing the Therapeutic Potential of MRT-6160 in Inflammatory Bowel DiseaseIn a significant development in the field of inflammatory bowel disease (IBD) research, Monte Rosa Therapeutics, a leading biotechnology company, has presented compelling preclinical data at Digestive Diseas...
Financing Agreement

Monte Rosa Therapeutics Tackles Struggling Finances with Bold Public Offering Amidst Decline in Working Capital Ratio

Published Wed, May 15 2024 8:01 PM UTC


In the third quarter of 2023, Monte Rosa Therapeutics experienced an increase in current liabilities, resulting in the company s working capital ratio falling to 8.09. This figure places them at a disadvantage when compared to 56 other companies in the industry that have achieved higher working capital ratios during the same period. Furthermore, when comparing their cur...






Monte Rosa Therapeutics Inc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com